Nowadays many authors suggest the use ofintravitreal triamcinolone acetonide (TA) for the treatment of vitreoretinal diseases, although it can be associated with a high risk of local toxicity. In order to develop a safer injection for clinical use, the purpose of our study is to evaluate the in situ safety of two different triamcinolone preparations, a commercially available TA and a micronized triamcinolone. The experiments were performed on 18 adult male age-matched New Zealand rabbits. The clinical examination included funduscopy with an indirect ophthalmoscope and intraocular pressure (lOP) measurement. At the end of the clinical observations, the animals were sacrified and the eyes enucleated and processed for the morphological evaluation. In our study the main side effect observed was the lOP elevation in the group injected with triamcinolone acetonide. In addition, in the TA-injected group, one eye was enucleated following an endophthalmitis. Our study highlights that doses as low as 4 mg of triamcinolone acetonide injected into the rabbit vitreous may have a local toxic effect in terms of lOP elevation, endophthalmitis occurrence and changes in the retinal morphology. In contrast, the micronized triamcinolone injection shows a less toxic effect in situ, thus suggesting the alternative use of this more reliable preparation which seems to be safer for a clinical use.
Intraocular
neovascularization, often accompanied and stimulated by intraocular inflammation, has remained an important problem in clinical ophthalmology. Moreover, defects in the blood-retina barrier due to capillary leakage, with accumulation offluid in the intraretinal and subretinal spaces of the macula, are other major causes of impaired vision. The reasons for such conditions are various and include diabetic retinopathy, retinal vein occlusions and uveitis, to mention only a few.
Corticosteroids are known to reduce intraocular inflammation and tighten the capillary walls, and, depending on the concentration, to suppress cell proliferation. For these reasons steroids have been widely used in the treatment ofmany ocular diseases, applied topically as drops, given sistemically or injected into the subconjunctival or sub-Tenon space. Often, however, the intraocular concentration of corticosteroids is too low or the systemic side effects are too pronounced to allow an extended treatment.
In order to overcome these limitations, Machemer et al. have suggested the intravitreal application of a crystalline form of steroid that provides intraocularly available drug for a considerably longer period (l) . In particular, the intravitreal injection of triamcinolone acetonide . (TA) (9a-fluoro-16a-hydroxyprednisolone) was first proposed in an experimental study by Tano et al (2) . Today, many authors suggest the use of triamcinolone for the treatment of vitreoretinal diseases (3) (4) . Although TA is only intermediate in its anti-inflammatory action compared with other corticosteroids, it has the advantage of a longer absorption time than soluble steroids (5) (6) .
Drug delivery into the posterior segment ofthe eye alleviates some issues, such as bioavailability, and can lead to the improvement of its therapeutic effects by increasing the intraocular drug concentration (7). However, it can be associated with a high risk oflocal toxicity. The side-effects of ocular corticosteroid therapy are well known and include elevation of intraocular pressure, caractogenesis, and infectious or sterile ophthalmitis (8) (9) (10) .
It may be significant that triamcinolone acetonide is usually not found in the serum shortly after its intravitreal application, suggesting that major systemic side-effects are not very probable (11) .
With regard to the lOP elevation, previous studies have suggested that the TA may obstruct the trabecular meshwork of the anterior chamber, thus blocking the aqueous humor outflow (12) (13) . Regarding the risk of an infectious endophtalmitis, it may partially depend on the setting of the intravitreal injection itself. In fact previous studies suggest that ifthe injection is performed under sterile conditions, the risk may be less (14) .
A sterile endophtalmitis has been reported to occur after an intravitreal TA injection (15) (16) . It is possible that the solvent agent of commercially available TA is responsible for the sterile intraocular inflammation after the injection, because pure TAhas been shown to be safe in animal studies (10, 15) .
Regarding the potential retinal toxicity of intravitreal TA, some studies have shown the safety of TA for intravitreal injection (17) (18) , while others demonstrated that TA may have toxic effects on retinal pigmented epithelium and glial cells (19) (20) .
Since the intravitreal TA is increasingly being used, it is important to be aware of the risks associated with this procedure. In order to develop a more reliable, stable and safe injection for clinical use, the aim of the present study is to evaluate the in situ safety of the intravitreal injection of two different triamcinolone preparations, a commercially available TA and a micronized triamcinolone.
MATERIALS AND METHODS
The experiments were performed on 18 adult male age-matched albino rabbits of the New Zealand strain (purchased from Charles River Laboratories Italia, Calco, Lecco, Italy), weighing 1.5 ± 0.2 kg. They were housed two per cage under standard conditions (21DC, 12 h light/l2 h dark cycle, food and water ad libitum) for an adaptation period of 1 week, after which they were admitted to the experimental procedures. Four rabbits served as controls and were injected with saline solution. Since ocular pigmentation may indirectly protect against the toxic effects of the drug, albino rabbits were chosen for our study (21) . All animals were handled in accordance with ARVO Statement for the use ofAnimals in Ophtalmic and Vision Research and examined with this clinical schedule: baseline, 15 days , 30 days, 45 days, because the triamcinolone acetonide has been shown to remain in the vitreous for an average time of 41 days after the intravitreal injection (22) . This clinical examination included: funduscopy with an indirect ophthalmoscope and intraocular pressure measurement.
At the end of the clinical observations, the animals were sacrificed with an intravenous injection of pentobarbitone sodium. Immediately after death, the eyes were enucleated and processed for the histologic evaluation.
Fundus examination
Phenylephrine 10% .eye drops combined with tropicamide 1% were used to dilate the pupil. Fundus examination was made in all animals by indirect binocular ophthalmoscopy, using a 20 D Goldman lens.
The evaluations of the vitreous opacity were carried out using the binocular indirect ophthalmoscopy score (BIO score), following the International Uveitis Study Group (IUSG) guide lines (23) and the standardization of uveitis nomenclature (SUN) working group (24) .
Surgical procedure
Rabbits were prepared for the intravitreal injection with ofloxacine eye drops (Exocin® eye drops, Allergan Ltd, Marlow, UK) 6 times/day for 3 days before the surgical procedure, and 4 days after.
The triamcinolone acetonide (Kenalog-40®, BristolMyers-Squibb Company, Princeton, NJ) was prepared in a syringe with a 27 Gauge (G) needle. A volume ofO.l ml was injected into the eyes (4 mg dose).
The micronized triamcinolone (TM) (lVT®, SOOFT Italia s.r.l., Montegiorgio-AP, Italy) was supplied in disposable preservative-free syringes with 27 G needle. A volume ofO.l ml was injected in the eyes (4 mg dose).
Before the injection, the eyes received a single use topical oxybuprocaine eye drops (OXB) (Novesine®, Novartis Phanna, Switzerland). Povidone iodide at 5% was instilled onto the ocular surface 3 minutes prior to injection. Periocular skin, eyelid margins, and eyelashes were cleaned with 10% povidone iodine. An eyelid speculum was inserted, ensuring that it was wellpositioned underneath the eyelids to direct the eyelashes away from the field. The injection was performed inferotemporally at 3 mm from the limbus.
Intraocular Pressure (l OP) Measurement lOP was checked using applanation method by tonopen (Tono-Pen XL, Applanation tonometer, Medtronic Ophthalmics); the rabbits were topically anesthetized using OXB.
The animals were then sacrificed with an intravenous injection of pentobarbitone sodium. Immediately after death, the eyes were enucleated and processed for the histologic evaluation.
Scanning electron microscopy (SEM)
The enucleated eyes were cut in half at the equator, fixed in 2% glutaraldeyde in O.I M cacodylate buffer (pH 7.4), post-fixed in 1% osmium tetroxide, dehydrated in increasing ethanol concentrations and then CPD-dried. They were then mounted on stubs and gold-sputtered . The observations were carried out with a Philips 505 scanning electron microscope.
Statistical analysis
The statistical analysis of the results was carried out with a blind method by a person not involved in the study, using the software SAS (version 8.1). The type of intravitreal injection into the eyes was randomized for each rabbit using the program in the SPSS database (SPSS, Chicago, Illinois, USA). The results were analyzed using Student's r-test for unpaired data. P values less than 0.05 were considered statistically significant.
RESULTS

Clinicalfindings
A marked progression of cataract and corneal abnormalities were not observed in the rabbits that received both acetonide and micronized triamcinolone .
In the group that received the triamcinolone acetonide, one rabbit had the eye enucleated following an endophthalmitis after 4 days.
Regarding the lOP (Fig. 1 
Fig. 2. A. vitreous opacity evaluation carried out using the binocular indirect ophthalmoscopy score (BIG score) in the eyes treated with triamcinolone acetonide (TA) and in the micronized triamcinolone (TM) injected-eyes at "day 0". The number of eyes showing different BIG score values is shown. B. vitreous opacity evaluation carried out using the binocular indirect ophthalmoscopy score (BIG score) in the eyes treated with triamcinolone acetonide (TA) and in the micronized triamcinolone (TM) injected-eyes at "day 45" offollow-up. The number ofeyes showing different BIG score values is shown. One eye was enucleated and not considered in the TA group.
group treated with micronized triamcinolone with respect to the baseline, whereas in the group injected with triamcinolone acetonide the lOP showed a statistically significant increase at 15 days (p < 0.05), 30 days (p < 0.001) and 45 days (p < 0.001) (Fig. 1) .
Immediately after the injection (at "day 0"), the BIO score was 0+ in 15 and 1+ in 3 of the eyes treated with TM. On the contrary, in the group that received the TA there were 4 eyes with BIO score 4+, 7 with 3+, 6 with 2+ and 1 with 1+ ( Fig. 2A) . At 45 days offollow-up, the BIO score was 0+ in all the eyes treated with TM, while in the group injected with TA the mo score was: 4+ in 1 of the eyes, 3+ in 3, 2+ in 4 of the eyes, 1+ in 6, and 0+ in 3 of the eyes (Fig. 2B) .
Morphological findings
Morphological analysis of the rabbit eyes, evaluated by SEM, is reported in Fig. 3 . In particular, sections A-D show the morphology of the retinal vessels. In the eyes treated with TA it is possible to notice the presence of caliber irregularity and narrowing, together with multifocal areas of haemorrhage. In addition we can observe the deposition of drug particles on the retinal surface (Fig 3, sections A and B) . On the contrary, the retinal vessels of the eyes injected with the micronized triamcinolone have a more regular caliber, without haemorrhages. We can also notice the absence of triamcinolone deposits (Fig. 3, sections C and D) . Regarding the lens, none of the samples had any abnormalities demonstrated by SEM (data not shown).
Concerning the retinal layers the SEM examination shows an apparent shortening of the photoreceptor outer segments both,ip the group treated with TA and in the eyes injected with the micronized triamcinolone with respect to the controls. Moreover, in the TAtreated eyes we can observe the presence ofamorphous cellular debris on the outer retina surface (Fig. 3 , sections E, F and G).
DISCUSSION
Recent reports have shown a widespread use of intravitreal triamcinolone acetonide injections despite lack of convincing safety data. Altough it is generally believed that TA is relatively safe and non-toxic when administered intraocularly or in in vitro conditions (17) , the cytotoxicity should be characterized if TA is used with confidence in clinical practice.
For these reasons we conducted an investigation on rabbits to determine whether there are differences in the clinical and morphological responses to the intravitreal injections of two triamcinolone preparations, a commercial triamcinolone acetonide, and a micronized triamcinolone which has the advantage of stability and sterility. The micronized triamcinolone was in fact provided in single-use preservative-free syringes. Toxic preservatives in the vehicles of commercially available corticosteorids have been suggested as possible contributors to proliferative vitreoretinopathy (25) . Sterile endophthalmitis has also been reported to occur after an intravitreal injection of a corticosteroid, and the toxic effects of commercial vehicle preservatives have been proposed as a possible cause (10) .
In our study the main side effect observed was the lOP elevation in the group injected with triamcinolone acetonide, in agreement with previous studies (14) . Moreover, in the group treated with triamcinolone acetonide, one eye was enucleated following an endophthalmitis.
Despite the disinfection of the vials before use and although the injection was performed under sterile conditions, utilizing multiuse vials may increase the risk of endophthalmitis.
Another important issue is the BIO score. Our BIO score analysis at "day 0" highlights that the eyes injected with TA had a higher vitreous torbidity, while the eyes treated with TM showed a better distribution of the drug in the vitreous cavity. In addition, this difference remained stable at 45 days of follow-up. These data could represent a basis for future application in clinical practice because patients may have less complaints about vitreous opacities.
Concerning our morphological observations, we have demonstrated, in the eyes treated with TA, the presence of drug deposits (i.e. triamcinolone crystals) on the retinal surface, in agreement with previous findings (13) .
Regarding the retinal vessels, our SEM analysis shows the presence of narrowing and haemorrhages in the eyes injected with triamcinolone acetonide, whereas in the micronized triamcinolone-treated eyes the vessels have a more regular caliber and we noted the absence of haemorrhages.
With regard to the retinal haemorrage, it has been previously suggested that it may be caused by the vehicle used in the preparation of intravitreal TA (26) .
Finally, regarding the retinal layers, our results suggest the presence of damage to the outer retina after a single intravitreal injection of triamcinolone acetonide, in terms of photoreceptor injury leading to an accumulation of cellular debris, in agreement with previous studies (27) . In the eyes treated with micronized triamcinolone our observations emphasize a slight reduction in the outer segment length, without the accumulation of amorphous cellular particles.
In conclusion, this study demonstrates that doses as low as 4 mg of triamcinolone acetonide injected into rabbit vitreous may have a local toxic effect, in terms of lOP elevation, endophthalmitis occurrence and changes in the retinal morphology. In contrast, the micronized triamcinolone injection shows a less toxic effect in situ and, in addition, has the quality of stability and sterility.
For these reasons we suggest the alternative use of this more reliable preparation which seems to be safer for clinical use.
